David Grimwade

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 1.9K citations · Full text

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

David Grimwade · Blood · 2001 · 915 citations · Full text

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 812 citations · Full text

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · The Lancet Oncology · 2015 · 533 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +8